Antifungal Therapeutics and Resistance

Working Group of Fabio Gsaller

About

Our research focuses on the molecular investigation of antifungal drug mechanisms of action and to elucidate factors that contribute to antifungal resistance. We aim to acquire a more comprehensive understanding on the metabolic effects of antifungals as well as on the adaptive strategies employed by Aspergillus fumigatus to protect itself from antifungal compounds with the final goal to develop alternative strategies to treat fungal diseases.

- Transcriptional regulation based antifungal resistance
- Metabolic pathways targeted by antifungal drugs
- Novel tools facilitating genetic engineering
- Genetic manipulation of Aspergillus spp. - gene deletions, knock-ins, site-directed mutagenesis, conditional expression mutants
- Antifungal susceptibility testing - minimum-inhibitory-concentration determination, plate assay based resistance testing
- Gene expression analysis - reporter assays, qRT-PCR, Northern analysis
- Phenotypical analysis of mutant strains
- Microscopy - multicolor fluorescence microscopy, time-lapse
→ Show all publications on PubMed

Projects

Development of novel 5-fluorocytosine based antifungal therapeutics

People

Group Leader

Fabio Gsaller, PhD

Medical University of Innsbruck - Institute of Molecular Biology/Biocenter
Fabio.Gsaller@i-med.ac.at
+43 512 9003 70224

Group Members

Luis-Enrique Sastre Velasquez, MSc

PhD student, Resistance of Aspergillus fumigatus to 5-fluorocytosine; luis.sastre@i-med.ac.at

Alexander Kühbacher, MSc

technician; alexander.kuehbacher@i-med.ac.at

Petra Merschak, Ing

technician; petra.merschak@i-med.ac.at

Mandy Peiffer, BSc

MSc student; Reporter analysis of antifungal resistance associated genetic factors; Mandy.Peiffer@student.uibk.ac.at